Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.

Détails

ID Serval
serval:BIB_A1F302A9ACFD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Périodique
European Journal of Immunology
Auteur(s)
Garcia Casado J., Janda J., Wei J., Chapatte L., Colombetti S., Alves P., Ritter G., Ayyoub M., Valmori D., Chen W., Lévy F.
ISSN
0014-2980
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
38
Numéro
7
Pages
1867-1876
Langue
anglais
Résumé
Expression of the cancer/germ-line antigen NY-ESO-1 by tumors elicits spontaneous humoral and cellular immune responses in some cancer patients. Development of vaccines capable of stimulating such comprehensive immune responses is desirable. We have produced recombinant lentivectors directing the intracellular synthesis of NY-ESO-1 (rLV/ESO) and have analyzed the in vivo immune response elicited by this vector. Single injection of rLV/ESO into HLA-A2-transgenic mice elicited long-lasting B and T cell responses against NY-ESO-1. CD8+ T cells against the HLA-A2-restricted peptide NY-ESO-1(157-165) were readily detectable ex vivo and showed restricted TCR Vbeta usage. Moreover, rLV/ESO elicited a far greater anti-NY-ESO-1(157-165) CD8+ T cell response than peptide- or protein-based vaccines. Anti-NY-ESO-1 antibodies were rapidly induced after immunization and their detection preceded that of the antigen-specific CD8+ T cells. The rLV/ESO also induced CD4+ T cells. These cells played an essential role as their depletion completely abrogated B cell and CD8+ T cell responses against NY-ESO-1. The induced CD4+ T cells were primarily directed against a single NY-ESO-1 epitope spanning amino acids 81-100. Altogether, our study shows that rLV/ESO induces potent and comprehensive immune responses in vivo.
Mots-clé
Animals, Antibodies, Neoplasm/blood, Antigens, Neoplasm/immunology, Antigens, Neoplasm/metabolism, B-Lymphocytes/immunology, B-Lymphocytes/metabolism, CD4-Positive T-Lymphocytes/immunology, CD4-Positive T-Lymphocytes/metabolism, CD8-Positive T-Lymphocytes/immunology, CD8-Positive T-Lymphocytes/metabolism, Cancer Vaccines/immunology, Genetic Vectors, Humans, Immunization, Lentivirus, Lymphocyte Activation, Membrane Proteins/immunology, Membrane Proteins/metabolism, Mice, Mice, Transgenic, Receptors, Antigen, B-Cell/immunology, Recombinant Proteins/immunology, Vaccines, Synthetic/immunology
Pubmed
Web of science
Open Access
Oui
Création de la notice
12/10/2009 11:45
Dernière modification de la notice
20/08/2019 15:07
Données d'usage